[{"id":"adbd79f5-f22a-49aa-95c4-b0366ee2600a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02118337","created_at":"2021-06-02T00:52:55.507Z","updated_at":"2024-07-02T16:36:29.645Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies","source_id_and_acronym":"NCT02118337","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imfinzi (durvalumab) • MEDI0680"],"overall_status":"Completed","enrollment":" Enrollment 97","initiation":"Initiation: 05/19/2014","start_date":" 05/19/2014","primary_txt":" Primary completion: 03/17/2020","primary_completion_date":" 03/17/2020","study_txt":" Completion: 03/17/2020","study_completion_date":" 03/17/2020","last_update_posted":"2021-06-01"}]